Neola’s CEO: “The results from the usability study confirm our product”
Neola Medical's lung monitoring is user-friendly and safe. These are the results of the usability study cunducted during the spring.
- Successful study results are...
Medivir’s partner makes clinical progress in veterinary project
Medivir's partner Vetbiolix has reported positive results from a clinical proof-of-concept study in periodontal disease in dogs with one of Medivir's drug candidates. In...
Annexin towards completion of phase II study and share issue
After reporting promising efficacy signals in the ongoing phase II study on patients with the eye disease RVO, Annexin Pharmaceuticals now has a stronger...
Medivir continues to accelerate development with fostrox
Medivir's recently published Annual Report for 2023 focuses primarily on the drug candidate fostrox. Clinical data shows improved efficacy in patients with advanced primary...
CLS makes progress in prostate cancer in Europe and the US
Clinical Laserthermia Systems has treated its first prostate cancer patients in Italy and secured additional orders and agreements in the US. In addition, the...
Respiratorius’ US patent application reopens
After the initial rejection of Respiratorius' patent application, the US Patent and Trademark Office's Patent Trial and Appeal Board has now sided with the...
BiBB’s CEO: “Patient cases fortify our confidence in EndoDrill”
BiBBInstruments' cancer biopsy device, EndoDrill, has earned high praise from physicians who conducted the first clinical cases at Karolinska University Hospital in Stockholm, Sweden....
Prolight Diagnostics’ collaboration with G&H | ITL propels development
Prolight Diagnostics have appointed G&H | ITL for the development of its innovative point-of-care system, Psyros. The development project started in early 2023 and...
Abliva’s mission to become mitochondrial medicine powerhouse
Abliva’s CMO Magnus Hansson attended the 8th annual meeting of Mitochondrial Medicine – Therapeutic Development in March. The conference brings together leaders in translational...
BioInvent deepens collaboration with MSD
BioInvent has signed a new clinical collaboration and supply agreement with MSD. The agreement covers the evaluation of BioInvent’s anti-TNFR2 antibody BI-1910 in combination...